CLS strengthens its organization with Perjan Pleunis as new VP Marketing and Sales Europe
Lund, Sweden, 2021-02-03 - Clinical Laserthermia Systems AB (publ) (CLS), a developer of advanced innovative products for image guided high precision laser ablation, today announced that Perjan Pleunis is joining the company as new VP Marketing and Sales Europe. Perjan Pleunis, who is based in the Netherlands, has long and extensive experience of business development and sales of medtech products primarily for neuro applications and has previously held leading positions at companies such as Brainlab and Mevion Medical Systems in Europa. Perjan Pleunis will have a key role in the launch of a new generation of TRANBERG-products on the European market, with focus on image guided laser ablation treatment in prostate and brain. Pleunis holds a bachelor degree from Zuyd University of Applied Sciences in the Netherlands and starts his new position in February.
– I am very pleased that Perjan Pleunis joins the CLS team and I wish him a warm welcome. With his experience and network of medical professionals at hospitals all around Europe, Perjan will be a valuable team member at CLS. CLS is strengthening its team to be well positioned to capture new market opportunities as we continue to move forward. Together with our American partner ClearPoint Neuro we possess world leading experience and knowledge in advanced solutions to image guided laser ablation for high precision thermal therapies aimed at treatment of malignant and functional diseases in the prostate and brain, says Dan Mogren, acting CEO of CLS.
CLS markets and sells the TRANBERG® | Thermal Therapy System for high-precision, image-guided laser ablation treatments in the EU, targeting prostate cancer, pancreatic cancer, brain tumors and epilepsy, and in the U.S for soft tissue ablation such as prostate cancer. The system is also optimized for treatment with CLS’ proprietary imILT® protocol, with the potential to stimulate the immune system. Image guided means that the physician uses magnetic resonance images (MRI) or ultrasound (US) images, for example, to identify targets, guide placement of instruments and for monitoring during the ablation procedure.
Dan J. Mogren, CEO Clinical Laserthermia Systems AB (publ)
Ph: +46 – (0)705 – 90 11 40
E-mail: dan.mogren@clinicallaser.com
Clinical Laserthermia Systems AB (publ),develops and sells the TRANBERG®|Thermal Therapy System including specially designed sterile disposable products for minimally invasive treatment of cancerous tumors, in accordance with regulatory approvals in the EU and in the U.S. The products are marketed for image-guided laser ablation (FLA, LITT) and for treatment with the company’s interstitial laser thermotherapy, imILT®, with a potentially immune stimulating effect. The company, which is headquartered in Lund Sweden and has a subsidiary in Germany, USA and SIngapore, is listed Nasdaq First North Growth Market under the ticker CLS B. Certified Adviser (CA) is FNCA Sweden AB, Ph: +46 8 528 00 399. E-mail: info@fnca.se. Further information is available on www.clinicallaser.se.